The announcement of a public offering often leads to short-term negative impact on a company's stock price due to the potential dilution of existing shares. However, the influx of capital is critical for Voyager Therapeutics to continue funding its clinical trials and R&D, which could have long-term positive effects. The short-term impact is likely negative, but the importance of this capital infusion for the company's growth is significant.